GlassScriptPhysician profile
Linda Gatto
NPI 1497799639
$3,196.34
in general payments reported to CMS, 2019-2025
14 companies · $655 in 2025
The $655 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $318 · 2022: $269 · 2023: $499 · 2024: $1,456 · 2025: $655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,049 · Travel and Lodging: $561.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,049.16 |
| Travel and Lodging | $560.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,503.55 | 2023-2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $589.53 | 2021-2024 | Fasenra, Tezspire, Airsupra |
| United Therapeutics Corporation | $387.11 | 2021-2025 | Remodulin |
| Regeneron Healthcare Solutions, INC. | $174.46 | 2023-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $125.00 | 2025 | Uptravi, Opsumit |
| Takeda Pharmaceuticals U.S.A., INC. | $99.06 | 2023 | Glassia |
| Pulmonx Corporation | $74.36 | 2022 | |
| Glaxosmithkline, LLC. | $65.71 | 2023-2025 | Nucala, Trelegy Ellipta |
| Electromed, INC. | $52.48 | 2022 | |
| Amgen INC. | $45.33 | 2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $34.64 | 2022 | |
| 3b Medical, INC. | $17.56 | 2025 | Luna |
| Inogen, INC. | $15.43 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Chiesi USA, INC. | $12.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linda Gatto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.